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The activated NF-kB pathway rescues cells from apoptosis induced by DNA-damaging chemotherapy, including doxorubicin and alkylating agents. 5 By inhibiting NF-kB signalling, bortezomib sensitises cells to chemotherapyinduced apoptosis, including those known to be resistant to doxorubicin or melphalan. 4 The synergy between bortezomib and chemotherapy is most pronounced when bortezomib is given 24 h after chemotherapy. 5 Lonial et al. 6 have shown the safety of bortezomib plus HDM (Bor-HDM) conditioning in up-front auto-SCT, and reaffirmed pre-clinical data that synergy is optimised when bortezomib is delivered 24 h post-melphalan. More recently, also in up-front auto-SCT, the IFM group has not only shown safety but also achieved an impressive CR rate of 32%, with 70% of patients achieving at least a very good PR. 7 To our knowledge, there are no reports of Bor-HDM conditioning being used in the setting of multiply relapsed disease. Here, treatment options are limited and both haematological and non-haematological toxicity may be expected to be greater.
We conducted a retrospective review of 11 consecutive, heavily pre-treated patients undergoing a total of 12 Bor-HDM-conditioned auto-SCT at Peter MacCallum Cancer ) was administered on D À2. Dose was reduced to 140 mg/m 2 in two patients owing to renal impairment, defined as a glomerular filtration rate o30 mL/min. 8 Bortezomib was administered at a dose of 1.3-1.6 mg/m 2 on D À1. Stem cells were reinfused on day 0. Four patients also received post-transplant bortezomib, one on D þ 1, two on D þ 2 and one on D þ 1 and D þ 4.
Comparisons were made with respect to time to platelet and neutrophil recovery, platelet and red cell transfusion requirements and non-haematological toxicity. At day 100, patients were assessed for response, as defined in the International Myeloma Working Group uniform response criteria. 9 Statistical analysis was performed for platelet and neutrophil engraftment recovery times using SigmaPlot V11 (Systat Softwear Inc., Chicago, IL, USA), using t-tests for normally distributed data and Mann-Whitney Rank Sum tests for non-normally distributed data.
Demographic data for patients undergoing Bor-HDM conditioning and the historical cohort undergoing a second HDM alone-conditioned auto-SCT are shown in Table 1 .
When compared with all HDM-conditioned auto-SCT performed since 2001, there was no difference in time to neutrophil recovery (P ¼ 0.26). There was a non-significant trend toward slower platelet recovery (P ¼ 0.13; Table 2 ). Moreover, when compared with the historical cohort having a second HDM-conditioned auto-SCT, there was no delay in platelet (P ¼ 0.89) or neutrophil recovery (P ¼ 0.77).
Eight patients had previously been treated with the HDM-alone auto-SCT and subsequently, on relapse, went on to have a second auto-SCT conditioned with Bor-HDM. There was no significant difference in neutrophil (P ¼ 0.384) or platelet (P ¼ 0.381) recovery, while platelet and red cell transfusion requirements were similar ni the two procedures.
There was no excess non-haematological toxicity when compared with HDM-conditioning alone. A total of 4 of 12 procedures were complicated by microbiologically-proven infections. Mucositis requiring total parenteral nutrition occurred during 4 of 12 procedures, which is comparable to the historical second transplant group, in which 10 of 33 patients received total parenteral nutrition. There were no deaths.
At 100 days, there was a 100% overall response rate, with two CRs, one very good PR, six PRs and two minimal responses. The three patients who were never previously transplanted, each achieved a PR. At a median follow-up of 13.5 months (3.5-23), 9 of 11 patients are alive. Six patients have progressed, with a median time to progression of 7 months (5-19). Median follow-up for the remaining five patients is 5 months (3.5-14) .
Concordant with two earlier studies of Bor-HDM in previously untreated patients, 6, 7 these results show that the addition of bortezomib to HDM for conditioning before auto-SCT in multiple myeloma is safe, with no excess non-haematological toxicity, and does not delay neutrophil or platelet engraftment even in this heavily pre-treated population.
Although the primary purpose of our review was to illustrate the safety of delivery of Bor-HDM conditioning, preliminary efficacy data in our small group of heavily pretreated patients are encouraging.
Pre-clinical 5 and phase I 6 data indicate that the optimal timing of administration of a single dose of bortezomib is 24 h after melphalan, while the use of bortezomib post-stem cell infusion is attractive as a simple, safe method of in vivo purging. Bor-HDM conditioning can achieve an impressive response rate in up-front auto-SCT, 7 however, further studies are required to determine whether it leads to deeper and more durable remissions and improved OS.
